Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer von Yoshino, Takayuki, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Wainberg, Zev, Elez, Elena, Rodriguez, Javier, Fakih, Marwan, Ciardiello, Fortunato, Saxena, Kapil, Kobayashi, Kojiro, Bako, Emarjola, Okuda, Yasuyuki, Meinhardt, Gerold, Grothey, Axel, Siena, Salvatore

Volltext

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer von Cortés, Javier, Kim, Sung-Bae, Chung, Wei-Pang, Im, Seock-Ah, Park, Yeon Hee, Hegg, Roberto, Kim, Min Hwan, Tseng, Ling-Ming, Petry, Vanessa, Chung, Chi-Feng, Iwata, Hiroji, Hamilton, Erika, Curigliano, Giuseppe, Xu, Binghe, Huang, Chiun-Sheng, Kim, Jee Hyun, Chiu, Joanne W.Y., Pedrini, Jose Luiz, Lee, Caleb, Liu, Yali, Cathcart, Jillian, Bako, Emarjola, Verma, Sunil, Hurvitz, Sara A.

Volltext

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial von Siena, Salvatore, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Fakih, Marwan, Elez, Elena, Rodriguez, Javier, Ciardiello, Fortunato, Komatsu, Yoshito, Esaki, Taito, Chung, Ki, Wainberg, Zev, Sartore-Bianchi, Andrea, Saxena, Kapil, Yamamoto, Eriko, Bako, Emarjola, Okuda, Yasuyuki, Shahidi, Javad, Grothey, Axel, Yoshino, Takayuki

Volltext

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer von Cortés, Javier, Kim, Sung-Bae, Chung, Wei-Pang, Im, Seock-Ah, Park, Yeon Hee, Hegg, Roberto, Kim, Min Hwan, Tseng, Ling-Ming, Petry, Vanessa, Chung, Chi-Feng, Iwata, Hiroji, Hamilton, Erika, Curigliano, Giuseppe, Xu, Binghe, Huang, Chiun-Sheng, Kim, Jee Hyun, Chiu, Joanne W.Y, Pedrini, Jose Luiz, Lee, Caleb, Liu, Yali, Cathcart, Jillian, Bako, Emarjola, Verma, Sunil, Hurvitz, Sara A

Volltext

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTIN... von Raghav, Kanwal Pratap Singh, Yoshino, Takayuki, Guimbaud, Rosine, Chau, Ian, Van Den Eynde, Marc, Maurel, Joan, Tie, Jeanne, Kim, Tae Won, Yeh, Kun-Huei, Barrios, Daniel, Kobayashi, Kojiro, Bako, Emarjola, Aregay, Mehreteab, Meinhardt, Gerold, Siena, Salvatore

Volltext

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTIN... von Raghav, Kanwal Pratap Singh, Yoshino, Takayuki, Guimbaud, Rosine, Chau, Ian, Van Den Eynde, Marc, Maurel, Joan, Tie, Jeanne, Kim, Tae Won, Yeh, Kun-Huei, Barrios, Daniel, Kobayashi, Kojiro, Bako, Emarjola, Aregay, Mehreteab, Meinhardt, Gerold, Siena, Salvatore

Volltext

Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-u... von Hamilton, Erika P., Bragaia, Vanessa PETRY HELENA, Yeo, Winnie, Kim, Sung-Bae, Bianchini, Giampaolo, Yamashita, Toshinari, Yonemori, Kan, Inoue, Kenichi, Curigliano, Giuseppe, Hurvitz, Sara A., Cortes, Javier, Iwata, Hiroji, Cathcart, Jillian, Liu, Yali, Lee, Caleb C., Bako, Emarjola, Kim, Rachel, Im, Seock-Ah

Volltext

Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the... von Hurvitz, Sara, Kim, Sung-Bae, Chung, Wei-Pang, Im, Seock-Ah, Park, Yeon Hee, Hegg, Roberto, Kim, Min-Hwan, Tseng, Ling-Ming, Petry, Vanessa, Chung, Chi-Feng, Iwata, Hiroji, Hamilton, Erika, Curigliano, Giuseppe, Xu, Binghe, Lee, Caleb, Liu, Yali, Cathcart, Jillian, Bako, Emarjola, Verma, Sunil, Cortés, Javier

Volltext

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DES... von Yoshino, Takayuki, Di Bartolomeo, Maria, Raghav, Kanwal Pratap Singh, Masuishi, Toshiki, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Wainberg, Zev A., Elez, Elena, Rodriguez, Javier, Fakih, Marwan, Ciardiello, Fortunato, Saxena, Kapil, Kobayashi, Kojiro, Bako, Emarjola, Okuda, Yasuyuki, Meinhardt, Gerold, Grothey, Axel, Siena, Salvatore

Volltext

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 von Siena, Salvatore, Di Bartolomeo, Maria, Raghav, Kanwal Pratap Singh, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Fakih, Marwan, Elez, Elena, Rodriguez, Javier, Ciardiello, Fortunato, Saxena, Kapil, Yamamoto, Eriko, Bako, Emarjola, Okuda, Yasuyuki, Shahidi, Javad, Grothey, Axel, Yoshino, Takayuki

Volltext

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DES... von Yoshino, Takayuki, Di Bartolomeo, Maria, Raghav, Kanwal Pratap Singh, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Wainberg, Zev A., Elez, Elena, Rodriguez, Javier, Fakih, Marwan, Ciardiello, Fortunato, Saxena, Kapil, Kobayashi, Kojiro, Bako, Emarjola, Okuda, Yasuyuki, Meinhardt, Gerold, Grothey, Axel, Siena, Salvatore

Volltext